Caring For Frontline Workers Conversation followed by audience Q+A
Anthony Back, MD (moderator)
Alexander Belser, PhD
Pamela Kryskow, MD
COVID-19 has exacerbated a long-simmering crisis in healthcare of clinician burnout and despair. Guided by the desire to reconnect to purpose within their own practices, physicians Anthony Back and Pamela Kryskow and psychologist Alexander Belser share their research into how psychedelic therapies might help clinicians overcome burnout and build stronger connections to their colleagues, patients and practices in the process. As frontline industries lose workers to what’s being called, ‘The Great Resignation,’ it’s essential to expand our thinking about how to help heal and support the people on whom we all depend.
Northern Lights: The Canadian Movement To Make Psychedelic Therapy Available at End Of Life Panel followed by audience Q+A
Trevor Millar, Social-Entrepreneur (moderator)
Thomas Hartle, Patient Advocate
Laurie Brooks, Patient Advocate
Dave Phillips, Therapist
In August 2020, Laurie Brooks and Thomas Hartle became the first Canadians to legally undergo psilocybin-assisted therapy to help process the prospect of death from cancer. Hear from therapists, patients and advocates about the movement to make psychedelic therapy a sanctioned treatment for those with serious illness and at end of life.
The Case For Real-World Evidence
Conversation followed by audience Q+A
Naheed Dosani, MD (Moderator), Palliative Care Physician
Noah Craft, MD, PhD, Co-Founder & Co-CEO, People Science
Belinda Tan MD, PhD, Co-Founder & Co-CEO, People Science
While randomized controlled trials are integral to the development and approval of many modern medicines; there’s important data that may be missed through such a narrow lens. Physicians Belinda Tan, MD PhD, Noah Craft, MD, PhD and Naheed Dosani, MD are committed to designing more inclusive models of inquiry to better understand what works in the real world and how those benefits might be extended to all in need.
Different Lenses on Psychedelics
Andrew Lee, VC Investor and Advisor (Moderator)
Victoria Hale, PhD, Board Chair, MAPS.org and CEO/Co-Founder of Sacred Medicines
Ben Lightburn, CEO and Co-Founder of Filament Health
Srinivas Rao, MD, PhD, Co-founder and Chief Scientific Officer at atai Life Sciences
The future of psychedelic therapies will depend in a large part on the avenues by which these treatments are brought to market. Hear from leading pharmaceutical executives Srinivas Rao MD, PhD, Victoria Hale, PhD and Ben Lightburn about the medicines they’re focusing on, their strategies for development and potential channels for distribution, and how these decisions might impact who gets them and how.